Literature DB >> 20732465

Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults.

Maria Luiza Silva1, Marina Angela Martins, Luçandra Ramos Espírito-Santo, Ana Carolina Campi-Azevedo, Denise Silveira-Lemos, José Geraldo Leite Ribeiro, Akira Homma, Erna Geessien Kroon, Andréa Teixeira-Carvalho, Silvana Maria Elói-Santos, Olindo Assis Martins-Filho.   

Abstract

The mechanisms of immune response following yellow fever (YF-17DD) vaccination are still poorly understood. In this study, we have performed a longitudinal investigation (days 0, 7, 15 and 30) to characterize the cytokine profile of innate and adaptive immunity following YF-17DD first-time vaccination. Data from non-stimulated cultures demonstrated a prominent participation of the innate immunity with increased frequency of TNF-α(+) neutrophils and IFN-γ(+) NK-cells at day 7 besides TNF-α(+) monocytes at day 7, day 15 and day 30. Increased frequency of IL-10(+) monocytes was observed at day 15 and day 30, and decreased percentage of IL-4(+) NK-cells were detected at day 7, day 15 and day 30. Time-dependent and oscillating cytokine pattern was observed in CD4(+) T-cells, with low percentage of IL-12(+), IL-4(+) and IL-10(+) cells at day 7 and increased frequency of TNF-α(+) cells at day 15 besides IFN-γ(+) and IL-5(+) cells at day 15 and day 30. Later changes with increased percentage of IL-12(+) and IL-5(+)CD8(+) T-cells were observed at day 30. Increased frequency of IL-10(+) B-cells was observed at day 15, when seroconversion was detected in all vaccinees. The overall cytokine analysis of non-stimulated leukocytes showed a transient shift towards a pro-inflammatory profile at day 7, mainly due to changes in the innate immunity, which draws back toward a mixed/regulatory pattern at day 15 and day 30. The changes induced by the in vitro YF-17DD vaccine-stimulation were mainly observed at day 0 and day 7 (before seroconversion) with minor changes at day 15 and day 30 (after seroconversion). These data support the hypothesis that a complex network with mixed pro/anti-inflammatory cytokine profile is associated with the establishment of the protective immunity following YF-17DD primo-vaccination, free of adverse events.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20732465     DOI: 10.1016/j.vaccine.2010.08.046

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  24 in total

Review 1.  The yellow fever 17D virus as a platform for new live attenuated vaccines.

Authors:  Myrna C Bonaldo; Patrícia C Sequeira; Ricardo Galler
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

2.  Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.

Authors:  Enoch Muyanja; Aloysius Ssemaganda; Pearline Ngauv; Rafael Cubas; Helene Perrin; Divya Srinivasan; Glenda Canderan; Benton Lawson; Jakub Kopycinski; Amanda S Graham; Dawne K Rowe; Michaela J Smith; Sharon Isern; Scott Michael; Guido Silvestri; Thomas H Vanderford; Erika Castro; Giuseppe Pantaleo; Joel Singer; Jill Gillmour; Noah Kiwanuka; Annet Nanvubya; Claudia Schmidt; Josephine Birungi; Josephine Cox; Elias K Haddad; Pontiano Kaleebu; Patricia Fast; Rafick-Pierre Sekaly; Lydie Trautmann; Denis Gaucher
Journal:  J Clin Invest       Date:  2014-06-09       Impact factor: 14.808

Review 3.  Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day.

Authors:  Natalie D Collins; Alan D T Barrett
Journal:  Curr Infect Dis Rep       Date:  2017-03       Impact factor: 3.725

Review 4.  Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine.

Authors:  Huabin Liang; Min Lee; Xia Jin
Journal:  Cell Mol Immunol       Date:  2015-10-05       Impact factor: 11.530

5.  Identification of Anti-Trypanosoma cruzi Lead Compounds with Putative Immunomodulatory Activity.

Authors:  Dayane Andriotti Otta; Fernanda Fortes de Araújo; Vitor Bortolo de Rezende; Elaine Maria Souza-Fagundes; Silvana Maria Elói-Santos; Matheus Fernandes Costa-Silva; Raiany Araújo Santos; Heloísa Alves Costa; Jair Lage Siqueira-Neto; Olindo Assis Martins-Filho; Andréa Teixeira-Carvalho
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 6.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

7.  Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins.

Authors:  Eddie A James; Rebecca E LaFond; Theresa J Gates; Duy T Mai; Uma Malhotra; William W Kwok
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

8.  Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study.

Authors:  Anna H Roukens; Darius Soonawala; Simone A Joosten; Adriëtte W de Visser; Xiaohong Jiang; Kees Dirksen; Marjolein de Gruijter; Jaap T van Dissel; Peter J Bredenbeek; Leo G Visser
Journal:  PLoS One       Date:  2011-12-07       Impact factor: 3.240

Review 9.  Historical review of clinical vaccine studies at Oswaldo Cruz Institute and Oswaldo Cruz Foundation--technological development issues.

Authors:  Reinaldo de Menezes Martins; Cristina de Albuquerque Possas; Akira Homma
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-01-16       Impact factor: 2.743

10.  One-year timeline kinetics of cytokine-mediated cellular immunity in dogs vaccinated against visceral leishmaniasis.

Authors:  Christiane Costa-Pereira; Marcela L Moreira; Rodrigo P Soares; Bruno H Marteleto; Vitor M Ribeiro; Michelle H França-Dias; Ludmila M Cardoso; Kelvinson F Viana; Rodolfo C Giunchetti; Olindo A Martins-Filho; Márcio S S Araújo
Journal:  BMC Vet Res       Date:  2015-04-11       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.